Operations take hit in AstraZeneca cuts; Daiichi Sankyo earnings cut by Ranbaxy issues;

> About 1,300 operations and supply chain positions will be lost as part of AstraZeneca's ($AZN) 7,300 job cuts aimed at saving $1.6 billion by the end of 2014. AZ release | Piece  

> An executive with Japan's Daiichi Sankyo, whose earnings were undercut by issues related to a consent decree signed by its majority-owned subsidiary Ranbaxy Laboratories, said the company will do its "best to transfer to Ranbaxy all the necessary domestic know-how in manufacturing technology and quality assurance." Story    

> After a FDA pre-approval inspection, contract manufacturing organization Pharmaceutics International has started construction of a 24,000-sq.-ft. cGMP aseptic fill/finish manufacturing facility at its Hunt Valley, MD, campus. Release

> Vitaflo USA is recalling Batch Number 12832 of its Renastart 14.11 oz (400g) cans, manufactured by a contract manufacturer in the U.K., because some of the medical food shipped throughout the U.S. from Dec. 29  through Jan. 26 was incorrectly labeled. Recall

> Aptar Pharma, the Crystal Lake, IL, maker of nasal and pulmonary drug delivery devices, has opened a new manufacturing site in Mumbai, India, its second in Asia after Suzhou in China. Aptar release 

> Saudi Arabia-based Arabio, which last year opened a 10,000-sq.-meter manufacturing facility in Makkah, has appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Story 

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)